Visual Field Defect Estimation Using Sequentially Optimized Reconstruction Strategy on Healthy and Glaucoma Subjects
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Oct 25, 2017
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cataract yes or no
- • Age range 40 - 80 years
- • Normal visual field (MD: \< +2 dB)
- • Refractive error within ±5 dpt. spherical equivalent
- • Astigmatism of \< -3 dpt.
- • Visual acuity of ≥0.3 logMar (decimal ≥0.5)
- • Experience in perimetry (history of at least one perimetry examination)
- • False positive or negative errors each less than 20% in each examination
- • Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma
- • Early to moderate visual field loss (MD: +2 to +12 dB)
- • Written informed consent
- Exclusion Criteria:
- • Exclusion criteria are children (\<18 years old), inability to follow the procedure, insufficient knowledge of project language, the history of other ocular diseases than glaucoma or cataract or other conditions that might affect visual field testing (e.g. pituitary lesions, demyelinating diseases).
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
René G Höhn, M.D.
Principal Investigator
Department of Ophthalmology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials